Allogene Therapeutics logo

Allogene Therapeutics

A biotechnology company catalyzing cancer treatment through the development of CAR T therapy

214 employees · est. 2017 · South San Francisco, United...

VS
FibroGen, Inc. logo

FibroGen, Inc.

Committed to being a place where our people and science thrive.

347 employees · est. 1993 · San Francisco, United States

FibroGen, Inc. is the older company (2017 vs 1993).

Side-by-Side Comparison

Allogene Therapeutics FibroGen, Inc.
Founded
2017 1993 older
Headquarters
South San Francisco, United States San Francisco, United States
Employees
214 347
Industry
Biotechnology Biopharma, Biotechnology, Health Care
Funding Stage
IPO Post Ipo Equity
Total Funding
$1.05B $308.02M
Funding Rounds
4 7
Services
Development of CAR T cell products, Clinical trial management, Gene editing and engineering, Manufacturing of allogeneic therapies, Therapeutic innovation for cancer and autoimmune diseases R&D Pipeline Management, Clinical Trials Execution, Drug Development, Scientific Research and Innovation
Target Customers
Patients with blood cancers, Patients with solid tumors, Patients with autoimmune diseases, Healthcare providers, Biopharmaceutical partners Healthcare Providers, Medical Researchers, Pharmaceutical Investors, Patients with Prostate Cancer, Patients with Anemia
Taxonomy
Clinical-stage, Cancer Treatment, Immunotherapy, CAR T Therapy, AlloCAR T Products, Allogeneic Therapies, Oncology, Autoimmune Disease, Cell Therapy, Therapy Development, Biopharmaceuticals, Medical Innovation, South San Francisco Connective Tissue Growth Factor, Hypoxia-Inducible Factor Biology, Monoclonal Antibodies, HIF-PH Inhibitors, Anemia Treatment, Fibrotic Disease, Cancer Therapeutics, Pancreatic Cancer Treatment, Duchenne Muscular Dystrophy, Immuno-Oncology, Autoimmune Disorders, Biotechnology Research, Drug Development, Clinical Development
Website
allogene.com fibrogen.com
Allogene Therapeutics logo

About Allogene Therapeutics

Allogene Therapeutics, based in South San Francisco, is a clinical-stage biotechnology company spearheading the evolution of cancer treatment with its innovative AlloCAR T products. Founded in 2017, the company is at the forefront of developing allogeneic chimeric antigen receptor T cell therapies,...

FibroGen, Inc. logo

About FibroGen, Inc.

FibroGen, Inc., founded in 1993, is a United States-based company operating in the biopharma and biotechnology sectors. The company is dedicated to pioneering first-in-class therapeutics targeting significant unmet medical needs globally, with a focus on areas such as anemia, fibrotic disease, and c...

We will tell you when either one moves

BounceWatch watches Allogene Therapeutics and FibroGen, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Allogene Therapeutics and FibroGen, Inc. — by email.

Frequently Asked Questions

Allogene Therapeutics — A biotechnology company catalyzing cancer treatment through the development of CAR T therapy. FibroGen, Inc. — Committed to being a place where our people and science thrive.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Allogene Therapeutics has raised $1.05B while FibroGen, Inc. has raised $308.02M.
Allogene Therapeutics and FibroGen, Inc. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Allogene Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Allogene Therapeutics on 9 Jun 2026, and FibroGen, Inc. on 2 Apr 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy